A study showed that the 3-gene expression signatures composed of SCGB2A1, KLF4, and PPP1R14B can differentiate a group of circa 5% of cases with short survival in chronic lymphocytic leukemia (CLL) patients, which is useful for further studies regarding disease prognostication and drug response in CLL (Orgueira et al., 2019). Here, SCGB2A1 is linked to B-cell chronic lymphocytic leukemia.